...
首页> 外文期刊>Journal of clinical lipidology >Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis
【24h】

Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis

机译:低密度脂蛋白血液分离的纯合子家族性高胆固醇血症患者的胆固醇外流介质

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Homozygous familial hypercholesterolemia (FH) is a rare disorder that may affect 1 person per million. Early initiation of aggressive cholesterol-lowering therapy is essential to prevent premature coronary heart disease. Selective removal of low-density lipoprotein (LDL) by LDL apheresis is a reliable method of treatment. Methods and Results: Cholesterol efflux mediators of homozygous FH patients on weekly LDL apheresis were compared with those of age- and sex-matched heterozygous FH patients receiving oral medication only and with healthy control subjects. The data show that (1) compared with healthy controls, homozygous FH patients have significantly lower plasma levels of high-density lipoprotein cholesterol and apoA-I and significantly lower cholesterol-acceptor capacity of serum to promote cholesterol efflux from cholesterol-loaded THP-1 cells, combined with significantly lower peripheral blood mononuclear cell gene expression levels of ATP-binding cassette (ABC) transporter G1 and borderline-significantly lower levels of ABCA1 and scavenger receptor class B type I (SR-BI); and (2) compared with pre-LDL apheresis (a day before treatment), postapheresis (15 days later; on the day after the weekly treatment) levels of HDL cholesterol and apoA-I were significantly reduced, with no significant effect on cholesterol-acceptor capacity of serum or on peripheral blood mononuclear cell gene expression levels of the cellular transporters, except for a borderline-significant reduction in ABCA1 mRNA levels. Conclusions: The data showing decreased levels of cholesterol efflux mediators in plasma and cells may suggest that the overall cholesterol efflux capacity is impaired in homozygous FH patients. However, LDL apheresis may maintain cholesterol efflux capacity, despite a lowering levels of high-density lipoprotein cholesterol and apoA-I. ? 2013 National Lipid Association. All rights reserved.
机译:背景:纯合子家族性高胆固醇血症(FH)是一种罕见的疾病,可能影响到每百万人中有1人。尽早开始积极的降胆固醇治疗对于预防早发性冠心病至关重要。通过LDL血液分离术选择性去除低密度脂蛋白(LDL)是一种可靠的治疗方法。方法和结果:比较纯合子FH患者每周LDL血液采血的胆固醇外流介质与仅接受口服药物治疗的年龄和性别相匹配的杂合子FH患者以及健康对照者的胆固醇外流介质。数据显示(1)与健康对照组相比,纯合子FH患者血浆中高密度脂蛋白胆固醇和apoA-I的水平显着降低,并且血清中胆固醇的促胆固醇能力从载有THP-1的胆固醇流出明显降低。细胞,与外周血单个核细胞的ATP结合盒(ABC)转运蛋白G1的基因表达水平显着降低,以及边界水平的ABCA1和I类清道夫受体(SR-BI)显着降低; (2)与LDL之前的血液分离术(治疗前一天),放血后(15天后;每周治疗后的第二天)相比,HDL胆固醇和apoA-I的水平明显降低,对血清的受体能力或细胞转运蛋白在外周血单核细胞基因表达水平上的接受能力,ABCA1 mRNA水平的显着降低除外。结论:显示血浆和细胞中胆固醇外流介质水平降低的数据可能表明纯合子FH患者的总胆固醇外流能力受到损害。然而,尽管降低了高密度脂蛋白胆固醇和apoA-I的水平,但LDL血液分离术仍可以维持胆固醇外排的能力。 ? 2013年国家脂质协会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号